Cited by 237COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19

Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19

Open access
D’Agnillo, Felice, Walters, Kathie-Anne, Xiao, Yongli, Sheng, Zong-Mei, Scherler, Kelsey, Park, Jaekeun, Gygli, Sebastian, Rosas, Luz Angela +20 more·2021·Science Translational Medicine

Abstract

Lung epithelial and endothelial cell damage and defective lung tissue repair contribute to fatal COVID-19.

AI snapshot

Written from the paper’s full text.

TL;DR

Lung autopsy and antemortem plasma analyses from 18 fatal COVID-19 cases show progressive diffuse alveolar damage, alveolar-capillary barrier injury, defective lung repair, impaired fibrinolysis, and epithelial/endothelial cellular senescence. These findings outline a temporal framework linking viral load, thrombosis, fibrosis, and age-related risk pathways in fatal SARS-CoV-2 infection.

Key findings

  • In 18 fatal COVID-19 autopsy cases (mean age 67.7 years; range 39–101; 10 males, 8 females; symptom onset-to-death 3–47 days), all lungs showed diffuse alveolar damage (DAD), with acute DAD predominant at short symptom onset-to-death and fibrotic DAD at longer durations.
  • Alveolar-capillary barrier damage included reduced surfactant protein expression, loss of AT2/AT1 and basal epithelial cells, decreased E-cadherin, claudin-5, and collagen type 4, plus impaired repair markers such as decreased FGFR2, SOX2, ITGA6, FGF2, and stem cell factor.
  • Thrombosis and impaired fibrinolysis were prominent: increased lung/plasma PAI-1, VWF, tissue factor, and fibrin, with decreased plasma ADAMTS13; PAI-1 localized to unresolved clots and PAI-1–positive neutrophils.
  • Cellular senescence markers were modulated in lung epithelium and endothelium, including increased nuclear p21, γH2A.X, CDKN2A/CDKN1A, and decreased sirtuin-1; correlations included acute DAD with viral load (R = 0.565, P = 0.024), fibrotic DAD with age (R = 0.565, P = 0.015), fibrotic DAD with SOTD (R = 0.555, P = 0.017), and SOTD with viral load (R = −0.722, P = 0.001).

Methods

  • Case series of postmortem FFPE lung autopsy samples from 18 patients with fatal SARS-CoV-2 infection (March–July 2020) and antemortem plasma from 6 of these cases (11 samples total); normal control FFPE lung tissue from 10 individuals without COVID-19 and plasma from 10 healthy volunteers were used for comparisons.
  • Analyses included histology, immunohistochemistry, immunofluorescence, qRT-PCR for SARS-CoV-2 RNA, next-generation sequencing for viral genomes and host SNPs, Agilent whole-genome microarray expression profiling, and multiplex plasma protein measurements using Olink and Luminex platforms.
  • Statistical methods included Pearson correlation, Student’s t test, principal component analysis, Benjamini-Hochberg correction for multiple comparisons, and Ingenuity pathway analysis for gene ontology enrichment.

Limitations

  • The paper states that the overall number of patients was small and that larger autopsy studies are needed to examine demographics, comorbidities, and in-hospital interventions such as mechanical ventilation.
  • The paper notes uncertainty about whether the available lung specimens used for imaging and transcriptomic analyses were representative of the whole lung.
  • The paper states that because all cases were fatal, it is unknown to what extent these pathological processes occur in mild-to-moderate, hospitalized nonfatal, or long-term sequelae cases; the text also makes evident that the plasma subset was only 6 patients, limiting analysis of clinical variables.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abj7790

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 64 cited sources checked · 0 supported · 0 flagged

  • Findingown data

    Transcripts associated with the reactive oxygen species response were modulated in lung tissue.

    “Transcripts associated with the reactive oxygen species (ROS) response were also modulated in lung tissue (Fig. 3D).”
    Quote in the paperNot a substantial claim
  • Findingown data

    Plasma concentrations of IFNLR1, DDX58, and leukemia inhibitory factor were significantly elevated in patients with COVID-19 compared to normal healthy volunteers.

    “Multiplex measurements of immune response proteins in antemortem plasma samples from patients with COVID-19 (n = 6 patients sampled up to four times before death; n = 11 samples total) demonstrated that concentrations of IFN-related proteins IFNLR1, DDX58, and leukemia inhibitory factor were significantly (P < 0.05) elevated compared to normal healthy volunteers (n = 10) (fig. S8B).”
    Quote in the paperNot a substantial claim
  • Findingown data

    FGFR2 and SOX2 transcripts were decreased in lung tissue from patients with COVID-19.

    “However, FGFR2 and SOX2 transcripts were decreased, as were transcripts of other genes involved in stem cell renewal and differentiation (BMP4 and BMPR1A) (30).”
    Quote in the paperSubstantial claim
  • Findingown data

    Postmortem lung sections from all 18 cases showed DAD as the predominant histopathologic finding, ranging from acute DAD through organizing and late fibrotic DAD.

    “The postmortem lung sections from all 18 cases showed DAD as the predominant histopathologic finding, ranging from acute DAD through organizing and late (fibrotic)–stage DAD (fig. S3 and table S11).”
    Quote in the paperSubstantial claim
    • Rests on an assumption: The postmortem lung autopsy findings reflect the antemortem pathophysiological processes of fatal COVID-19.
  • Findingown data

    Cases with longer illness duration displayed a pattern of multiple colocalized fibrin and tissue factor patches or fibrin balls in alveolar spaces that also expressed Col 1 but not αSMA.

    “The first pattern featured multiple colocalized fibrin and tissue factor patches or fibrin “balls” in alveolar spaces that also expressed Col 1 but not αSMA (Fig. 3B).”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
  • May combine two claims. 29
  • Classified as probably not a substantial claim. 13
  • May combine two claims.

    Findingown data

    CitH3-positive neutrophils were predominantly located in alveolar spaces and were more widespread in lungs from cases with short-duration disease.

    “These CitH3-positive neutrophils were predominantly located in alveolar spaces and were more widespread in lungs from cases with short-duration disease (fig. S15B).”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
  • May combine two claims.

    Findingown data

    ITGA6 expression was decreased at both the mRNA level in lung and the protein level in plasma in patients with COVID-19.

    “Expression of ITGA6, a cell surface marker of lung basal cells (28, 32), was decreased at both the mRNA level in lung (Fig. 1D) and at the protein level in plasma (Fig. 1E).”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Microarray analyses identified reduced transcripts encoding endothelial junction proteins and adhesion molecules including ENG, PECAM1, VCAM1, and MCAM, and increased transcription of angiopoietin-2.

    “Microarray analyses also identified reduced transcripts encoding endothelial junction proteins and adhesion molecules, including ENG, PECAM1, VCAM1, and MCAM as well as increased transcription of the gene encoding angiopoietin-2, a negative modulator of endothelial barrier dysfunction (fig. S12).”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Cases with intermediate illness duration showed less widespread intra-alveolar fibrin and tissue factor expression but were associated with widespread AT2 cell hyperplasia.

    “Cases with intermediate illness duration showed less widespread intra-alveolar fibrin and tissue factor expression but were associated with widespread AT2 cell hyperplasia, a hallmark of organizing DAD (figs. S3F and S11, A and C).”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
  • May combine two claims.

    Findingown data

    In longer-duration cases, fewer MPO-positive neutrophils were generally detectable, and these cells were primarily found in alveolar fibrin balls but not in interstitial fibrotic areas.

    “In longer-duration cases, fewer MPO-positive neutrophils were generally detectable, and these cells were primarily found in alveolar fibrin “balls” but not in the interstitial fibrotic areas.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
  • May combine two claims.

    Findingown data

    Expression of genes encoding surfactants A, B, C, and D was decreased in lung tissue from patients with COVID-19 and correlated significantly with viral load, with greater loss in patients with higher viral loads.

    “The expression of genes encoding surfactants A, B, C, and D was decreased in lung tissue from patients with COVID-19 and correlated significantly (≥0.6) with viral load, with greater loss of expression observed in patients with higher viral loads (Fig. 2B).”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    There was increased expression of genes encoding numerous collagens, including Col11A1 and Col14A1, which showed a positive correlation with symptom onset-to-death time.

    “Consistent with gene ontology analysis, there was increased expression of genes encoding numerous collagens, including some (e.g., Col11A1 and Col14A1) that showed a positive correlation with SOTD (Fig. 4B).”
    Quote in the paperSubstantial claim
    • Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
  • May combine two claims.

    Findingown data

    Vessels containing clots typically showed reduced and discontinuous staining for endothelial junction markers and were more frequently observed in short and intermediate SOTD cases than in long-duration cases.

    “Vessels containing clots typically showed reduced and discontinuous staining for endothelial junction markers and were more frequently observed in short and intermediate SOTD cases than in long-duration cases.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.
  • May combine two claims.

    Findingnone given

    In short SOTD cases, alveolar-capillary breakdown coincided with prominent recruitment of MPO-positive neutrophils in damaged alveoli with excessive fibrin and tissue factor deposition, in thickened alveolar interstitial spaces, and along the endothelial lining of injured blood vessels.

    “In short SOTD cases, alveolar-capillary breakdown coincided with prominent recruitment of MPO-positive neutrophils in damaged alveoli with excessive fibrin and tissue factor deposition, in thickened alveolar interstitial spaces, and along the endothelial lining of injured blood vessels.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Pulmonary SARS-CoV-2 infection damaged all three major components of the alveolar-capillary barrier, as evidenced by loss of alveolar epithelial and endothelial junction integrity, marked desquamation of lung AT1 and AT2 cells, and disruption of the Col IV-expressing alveolar basement membrane.

    “This lung autopsy series showed that pulmonary SARS-CoV-2 infection damaged all three major components of the alveolar-capillary barrier as evidenced by the loss of alveolar epithelial and endothelial junction integrity, marked desquamation of lung AT1 and AT2 cells, and disruption of the Col IV–expressing alveolar basement membrane.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Prominent pulmonary fibrosis was observed in this lung autopsy series and correlated with SOTD and patient age.

    “Prominent pulmonary fibrosis was observed in this lung autopsy series, consistent with previous reports (49–51), and correlated with SOTD and patient age (fig. S17).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [49] Ding M, Zhang Q, Li Q, Wu T, Huang YZ, Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19. Respir. Med 167, 105981 (2020). 32421546 PMC7167578 source

      Not checked in the free run.

    • cites [50] George PM, Wells AU, Jenkins RG, Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir. Med 8, 807– 815 (2020). 32422178 PMC7228727 source

      Not checked in the free run.

    • cites [51] Grillo F, Barisione E, Ball L, Mastracci L, Fiocca R, Lung fibrosis: An undervalued finding in COVID-19 pathological series. Lancet Infect. Dis 21, e72 (2021). 32735785 PMC7386839 source

      Not checked in the free run.

  • May combine two claims.

    Findingown data

    Clot-embedded PAI-1 cells stained positively for neutrophil markers MPO, neutrophil elastase, and CD15 but were negative for markers of T cells, B cells, monocytes/macrophages, and megakaryocytes/platelets.

    “These clot-embedded PAI-1 cells stained positively for neutrophil markers (MPO, neutrophil elastase, and CD15) (Fig. 6C) but were negative for markers of T cells (CD3), B cells (CD20), monocytes/macrophages (CD14/CD163), or megakaryocytes/platelets (CD61/CD42b) (fig. S21).”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Many genes associated with fibrinolysis were decreased in COVID-19 lung tissue relative to normal tissue, whereas some (F12 and ANXA2) showed increased expression.

    “Whereas some genes associated with fibrinolysis (F12 and ANXA2) showed increased expression, many were decreased in COVID-19 lung tissue relative to normal tissue (Fig. 5D).”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    The present study revealed evidence of viral antigen staining in pulmonary vascular endothelial cells in cases with short SOTD and high viral loads and a high frequency of thrombi in small- and medium-sized pulmonary blood vessels, particularly in short and intermediate SOTD cases.

    “The present study revealed evidence of viral antigen staining in pulmonary vascular endothelial cells in cases with short SOTD and high viral loads and a high frequency of thrombi in small- and medium-sized pulmonary blood vessels, particularly in short and intermediate SOTD cases.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Interpretationown data

    The data show that SARS-CoV-2 infection disrupts critical alveolar epithelial and endothelial function, leading to breakdown of the alveolar-capillary barrier.

    “Together, these data show that SARS-CoV-2 infection disrupts critical alveolar epithelial and endothelial function leading to breakdown of the alveolar-capillary barrier.”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Viral infection is mediated mainly by the binding of SARS-CoV-2 to the ACE2 receptor expressed on the surface of lung epithelial cells, endothelium, pericytes, and other cell types.

    “Viral infection is mediated mainly by the binding of SARS-CoV-2 to the angiotensin–converting enzyme 2 (ACE2) receptor expressed on the surface of lung epithelial cells, endothelium, pericytes, and other cell types (1–4).”
    Quote in the paperNot a substantial claim0 of 4 sources checked
    • cites [1] Batah SS, Fabro AT, Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Respir. Med 176, 106239 (2021). 33246294 PMC7674971 source

      Not checked in the free run.

    • cites [2] Bösmüller H, Matter M, Fend F, Tzankov A, The pulmonary pathology of COVID-19. Virchows Arch. 478, 137– 150 (2021). 33604758 PMC7892326 source

      Not checked in the free run.

    • cites [3] Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J, A systematic review of pathological findings in COVID-19: A pathophysiological timeline and possible mechanisms of disease progression. Mod. Pathol 33, 2128– 2138 (2020). 32572155 PMC7306927 source

      Not checked in the free run.

    • cites [4] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 324, 782– 793 (2020). 32648899 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Key risk factors associated with severe COVID-19 include advanced age (>80 years), diabetes, obesity, male gender, and hypertension.

    “Key risk factors associated with severe COVID-19 include advanced age (>80 years), diabetes, obesity, male gender, and hypertension (8–12).”
    Quote in the paperNot a substantial claim0 of 5 sources checked
    • cites [8] Borczuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M, Elsoukkary S, He B, del Vecchio C, Fortarezza F, Pezzuto F, Navalesi P, Crisanti A, Fowkes ME, Bryce CH, Calabrese F, Beasley MB, COVID-19 pulmonary pathology: A multi-institutional autopsy cohort from Italy and New York City. Mod. Pathol 33, 2156– 2168 (2020). 32879413 PMC7463226 source

      Not checked in the free run.

    • cites [9] de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, de Souza FD, Rodacki M, Bertoluci MC; Brazilian Diabetes Society Study Group (SBD), Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis. Diabetol. Metab. Syndr 12, 75 (2020). 32874207 PMC7456786 source

      Not checked in the free run.

    • cites [10] Ortiz-Prado E, Simbaña-Rivera K, Gómez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, Muslin C, Jaramillo AMG, Barba-Ostria C, Cevallos-Robalino D, Sanches-SanMiguel H, Unigarro L, Zalakeviciute R, Gadian N, López-Cortés A, Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn. Microbiol. Infect. Dis 98, 115094 (2020). 32623267 PMC7260568 source

      Not checked in the free run.

    • cites [11] Park SC, Won SY, Kim NH, Choi H, Youk TM, Lee HJ, Jeon HH, Risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections: A nationwide population-based study. Ann. Transl. Med 9, 211 (2021). 33708838 PMC7940880 source

      Not checked in the free run.

    • cites [12] Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJM, Baillie JK, Semple MG, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ 369, m1985 (2020). 32444460 PMC7243036 source

      Not checked in the free run.

  • May combine two claims.

    Interpretationown data

    The data suggest that even though lung repair processes are activated, key elements are impaired through damage and loss of critical lung basal cell populations, revealing a mechanism for impaired lung tissue repair in these patients with COVID-19.

    “Collectively, these data suggest that even though lung repair processes are being activated, key elements appear to be impaired through damage and loss of critical lung basal cell populations, revealing a mechanism for impaired lung tissue repair in these patients with COVID-19.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Premisecitation

    Direct viral infection of basal cells in fatal COVID-19 contrasts with fatal influenza viral infection, where viral replication does not occur in basal cells but associated secondary bacterial infections result in basal cell loss and lack of tissue repair and regeneration.

    “Direct viral infection of basal cells in fatal COVID-19 contrasts with fatal influenza viral infection, where viral replication does not occur in basal cells but associated secondary bacterial infections result in basal cell loss and lack of tissue repair and regeneration (42).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [42] Kash JC, Walters K-A, Davis AS, Sandouk A, Schwartzman LM, Jagger BW, Chertow DS, Li Q, Kuestner RE, Ozinsky A, Taubenberger JK, Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses. MBio 2, e00172– 11 (2011). 21933918 PMC3175626 source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    DAD and alveolar-capillary barrier breakdown are prominent pathological features of severe COVID-19.

    “DAD and alveolar-capillary barrier breakdown are prominent pathological features of severe COVID-19 (1–4).”
    Quote in the paperSubstantial claim0 of 4 sources checked
    • cites [1] Batah SS, Fabro AT, Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Respir. Med 176, 106239 (2021). 33246294 PMC7674971 source

      Not checked in the free run.

    • cites [2] Bösmüller H, Matter M, Fend F, Tzankov A, The pulmonary pathology of COVID-19. Virchows Arch. 478, 137– 150 (2021). 33604758 PMC7892326 source

      Not checked in the free run.

    • cites [3] Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J, A systematic review of pathological findings in COVID-19: A pathophysiological timeline and possible mechanisms of disease progression. Mod. Pathol 33, 2128– 2138 (2020). 32572155 PMC7306927 source

      Not checked in the free run.

    • cites [4] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 324, 782– 793 (2020). 32648899 source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    NETs promote tissue factor activation and fibrin deposition.

    “NETs have been shown to promote tissue factor activation and fibrin deposition, consistent with our observations, suggesting a role for NETs in intra-alveolar thrombosis and the formation or organization of platelet-rich clots (43, 45).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [43] Borges L, Pithon-Curi TC, Curi R, Hatanaka E, COVID-19 and neutrophils: The relationship between hyperinflammation and neutrophil extracellular traps. Mediat. Inflamm 2020, 1– 7 (2020). PMC7732408 33343232 source

      Not checked in the free run.

    • cites [45] Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, Tektonidou M, Konstantinidis T, Papagoras C, Mitroulis I, Germanidis G, Lambris JD, Ritis K, Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest 130, 6151– 6157 (2020). 32759504 PMC7598040 source

      Not checked in the free run.

  • May combine two claims.

    Interpretationown data

    Pulmonary SARS-CoV-2 infection disrupts the balance between normal tissue regeneration and pathological fibrosis, promotes increased and unresolving vascular thrombosis, and elicits production of damaging proinflammatory mediators and ROS.

    “Collectively, these findings indicate that pulmonary SARS-CoV-2 infection disrupts the balance between normal tissue regeneration and pathological fibrosis, promotes increased and unresolving vascular thrombosis, and elicits production of damaging proinflammatory mediators and ROS.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Interpretationown data

    In cases with a longer disease duration, disease progression led to excessive pulmonary fibrosis, loss of alveoli, and vascular remodeling.

    “Furthermore, in cases with a longer disease duration, disease progression led to excessive pulmonary fibrosis, loss of alveoli, and vascular remodeling.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Interpretationown data

    PAI-1-labeled neutrophils have a nonapoptotic and non-NET-producing phenotype.

    “These PAI-1–labeled neutrophils were also negative for cleaved caspase 3 and CitH3, suggesting a nonapoptotic and non–NET-producing phenotype, respectively (figs. S21 and S15D).”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Interpretationown data

    Both direct virus-induced cytopathic effects and host inflammatory and immune responses led to early pulmonary epithelial and endothelial injury, alveolar-capillary barrier dysfunction, impaired lung tissue repair processes, and widespread vascular thrombosis with reduced fibrinolysis.

    “Pathological observations indicated that both direct virus-induced cytopathic effects and host inflammatory and immune responses led to early pulmonary epithelial and endothelial injury, alveolar-capillary barrier dysfunction, impaired lung tissue repair processes, and widespread vascular thrombosis with reduced fibrinolysis.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Activated neutrophils, along with damaged epithelial and endothelial cells, release cytokines, chemokines, proteases, MMPs, and cytotoxic ROS, leading to DNA damage and perpetuation of alveolar destruction and respiratory dysfunction.
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Senescent cells exhibit a senescence-associated secretory phenotype (SASP) characterized by overproduction of proinflammatory molecules such as IL6, TGFβ, IL8, MCP-1, extracellular matrix remodeling enzymes (MMPs), serine/cysteine proteinase inhibitors (serpins), and tissue inhibitors of metalloproteinases.

    “Senescent cells exhibit a senescence-associated secretory phenotype (SASP) characterized by an overproduction of proinflammatory molecules such as IL6, TGFβ, IL8, MCP-1, extracellular matrix remodeling enzymes (MMPs), serine/cysteine proteinase inhibitors (serpins), and tissue inhibitors of metalloproteinases (61).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [61] He S, Sharpless NE, Senescence in health and disease. Cell 169, 1000– 1011 (2017). 28575665 PMC5643029 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    Because all cases in this study were fatal, it is unknown to what extent these pathological processes occur in mild to moderate or hospitalized, nonfatal COVID-19 cases or in cases with long-term sequelae after SARS-CoV-2 infection.

    “Last, because all cases in this study were fatal, it is unknown to what extent these pathological processes occur in mild to moderate or hospitalized, nonfatal COVID-19 cases or in cases with long-term sequelae after SARS-CoV-2 infection.”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Premisecitation

    A systematic review of 45 studies of chest computed tomography images of patients with COVID-19 demonstrated pulmonary fibrosis in 17% of patients, which was attributed to impaired healing after viral infection of lung AT2 cells.

    “A systematic review of 45 studies of chest computed tomography images of patients with COVID-19 demonstrated pulmonary fibrosis in 17% of patients, which was attributed to impaired healing after viral infection of lung AT2 cells (53).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [53] Ojha V, Mani A, Pandey NN, Sharma S, Kumar S, CT in coronavirus disease 2019 (COVID-19): A systematic review of chest CT findings in 4410 adult patients. Eur. Radiol 30, 6129– 6138 (2020). 32474632 PMC7261039 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    Ingenuity pathway analysis was used for gene ontology enrichment using Bonferroni correction.

    “Ingenuity pathway analysis was used for gene ontology enrichment using Bonferroni correction.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Clinical trials have shown reduced mortality in patients with influenza A/H7N9 virus-induced ARDS treated with transplanted MSCs.

    “Clinical trials have shown reduced mortality in patients with influenza A/H7N9 virus–induced ARDS treated with transplanted MSCs, and ongoing trials are currently investigating stem cell therapies for treating patients with COVID-19 (83).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [83] Yadav P, Vats R, Bano A, Bhardwaj R, Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. Life Sci. 263, 118588 (2020). 33049279 PMC7547615 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    A recent study reported a correlation between elevated PAI-1 plasma concentrations and circulating neutrophils in patients with COVID-19.

    “A recent study reported a correlation between elevated PAI-1 plasma concentrations and circulating neutrophils in patients with COVID-19 (58).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [58] Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M, Madison JA, Knight JS, Kanthi Y, Lawrence DA, Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. medRxiv, 1580 (2020). PMC7810990 33452298

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S1 (asserted), S3 (load-bearing).

    Premisecitation

    Targeting surfactant deficiency may improve respiratory function in patients with COVID-19.

    “Others have reported that targeting surfactant deficiency may improve respiratory function in patients with COVID-19 (80, 81).”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [80] Mirastschijski U, Dembinski R, Maedler K, Lung surfactant for pulmonary barrier restoration in patients with COVID-19 pneumonia. Front. Med 7, 254 (2020). PMC7256165 32574339 source

      Not checked in the free run.

    • cites [81] Piva S, DiBlasi RM, Slee AE, Jobe AH, Roccaro AM, Filippini M, Latronico N, Bertoni M, Marshall JC, Portman MA, Surfactant therapy for COVID-19 related ARDS: A retrospective case-control pilot study. Respir. Res 22, 20 (2021). 33461535 PMC7812332 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Treatment with corticosteroids has shown some efficacy against COVID-19.

    “Treatment with corticosteroids, that act on multiple anti-inflammatory pathways (75), has shown some efficacy against COVID-19 (76).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [76] Jensen MP, George M, Gilroy D, Sofat R, Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19. Br. J. Clin. Pharmacol 87, 845– 857 (2021). 32881064 source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Among patients who developed severe disease, median time to dyspnea was 5 to 8 days, median time to ARDS was 8 to 12 days, and median time to intensive care unit admission was 10 to 12 days after symptom onset.

    “Additional studies found that, among patients who developed severe disease, the median time to dyspnea was 5 to 8 days, the median time to ARDS was 8 to 12 days, and the median time to intensive care unit admission was 10 to 12 days after symptom onset (68–70).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [68] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497– 506 (2020). 31986264 PMC7159299 source

      Not checked in the free run.

    • cites [69] Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, Lu H, Liu J, Yang J, Dong Y, Pan D, Shu C, Li J, Wei J, Huang Y, Peng L, Wu M, Zhang R, Wu B, Li Y, Cai L, Li G, Zhang T, Wu G, Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol. 21, 904– 913 (2020). 32479787 PMC7259917 source

      Not checked in the free run.

    • cites [70] Zhou F, Yu T, du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395, 1054– 1062 (2020). 32171076 PMC7270627 source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Vascular dysfunction and thrombotic complications are hallmark features of COVID-19.

    “Vascular dysfunction and thrombotic complications are hallmark features of COVID-19 (55).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [55] Ahmed S, Zimba O, Gasparyan AY, Thrombosis in coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad. Clin. Rheumatol 39, 2529– 2543 (2020). 32654082 PMC7353835 source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Key clinical risk factors for developing severe COVID-19 such as advanced age, obesity, diabetes, and vascular disease are all characterized by activation or exacerbation of cellular senescence processes.

    “Key clinical risk factors for developing severe COVID-19 such as advanced age, obesity, diabetes, and vascular disease are all characterized by the activation or exacerbation of cellular senescence processes (66).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [66] Jia G, Aroor AR, Jia C, Sowers JR, Endothelial cell senescence in aging-related vascular dysfunction. Biochim. Biophys. Acta Mol. basis Dis 1865, 1802– 1809 (2019). 31109450 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    It is a potential concern whether the available lung specimens used for imaging and transcriptomic analyses were representative of the whole lung.

    “Another potential concern is related to lung tissue sampling and, specifically, whether the available lung specimens used for imaging and transcriptomic analyses were representative of the whole lung.”
    Quote in the paperNot a substantial claim
  • Classified as probably not a substantial claim.

    Study design and conductown data

    Control lung sections were histologically defined as normal by a certified pathologist using routine H&E staining.

    “These lung sections were histologically defined as normal by a certified pathologist using routine H&E staining.”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    ROS scavengers have shown efficacy in influenza.

    “ROS scavengers have shown efficacy in influenza (77), which, as noted, has certain clinical and pathologic similarities to COVID-19.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [77] Kash JC, Xiao Y, Davis AS, Walters KA, Chertow DS, Easterbrook JD, Dunfee RL, Sandouk A, Jagger BW, Schwartzman LM, Kuestner RE, Wehr NB, Huffman K, Rosenthal RA, Ozinsky A, Levine RL, Doctrow SR, Taubenberger JK, Treatment with the reactive oxygen species scavenger EUK-207 reduces lung damage and increases survival during 1918 influenza virus infection in mice. Free Radic. Biol. Med 67, 235– 247 (2014). 24140866 PMC3927540 source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Risk factors for developing severe COVID-19 such as advanced age, obesity, diabetes, and vascular disease are all associated with increased plasma PAI-1 concentrations.

    “It may be particularly relevant that risk factors for developing severe COVID-19 such as advanced age, obesity, diabetes, and vascular disease are all associated with increased plasma PAI-1 concentrations (59, 60).”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [59] Alessi MC, Juhan-Vague I, PAI-1 and the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol 26, 2200– 2207 (2006). 16931789 source

      Not checked in the free run.

    • cites [60] Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H, Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: Implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc. Res 66, 276– 285 (2005). 15820196 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    Statistical analysis included standard t test using Benjamini-Hochberg procedure to correct for the false-positive rate in multiple comparisons.

    “Statistical analysis included standard t test using Benjamini-Hochberg procedure to correct for the false-positive rate in multiple comparisons.”
    • Also stated in: § Microarray gene expression profiling · plain
      “The Benjamini-Hochberg procedure was used to correct for the false-positive rate in multiple comparisons.”
    Quote in the paperNot a substantial claim
41 of 41
  • The paper relies on this without support.

    The postmortem lung autopsy findings reflect the antemortem pathophysiological processes of fatal COVID-19.

    “Postmortem lung autopsy samples (n = 18) and antemortem plasma samples (from six of the cases) were collected from a case series of confirmed SARS-CoV-2–positive patients who died between March and July 2020.”
  • The paper relies on this without support.

    The 18 fatal COVID-19 autopsy cases are representative of fatal COVID-19 generally.

    “Postmortem lung autopsy samples (n = 18) and antemortem plasma samples (from six of the cases) were collected from a case series of confirmed SARS-CoV-2–positive patients who died between March and July 2020.”
  • The paper relies on this without support.

    The symptom onset-to-death interval reflects the duration and stage of pulmonary disease progression.

    “To further characterize histological indices of DAD progression in relation to clinical illness duration, serial lung sections were stained with H&E or for fibrin, tissue factor, collagen type 1 (Col 1), and α–smooth muscle actin (αSMA).”
  • The paper relies on this without support.

    Pathologic changes likely occurred asynchronously throughout the lung.

    “Although pathologic changes likely occurred asynchronously throughout the lung and each case examined resulted in a fatal outcome regardless of SOTD duration, these observations nevertheless suggested a temporal framework for disease progression that outlines a natural history and pathogenesis of SARS-CoV-2 infection (fig. S17).”
  • The paper relies on this without support.

    Activated neutrophils, along with damaged epithelial and endothelial cells, release cytokines, chemokines, proteases, MMPs, and cytotoxic ROS, leading to DNA damage and perpetuation of alveolar destruction and respiratory dysfunction.

    “Activated neutrophils, along with damaged epithelial and endothelial cells, release a host of cytokines, chemokines, proteases, MMPs, and cytotoxic ROS, leading to DNA damage and perpetuation of alveolar destruction and respiratory dysfunction.”
5 of 5

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A panel of senescence markers distinguishes nasopharyngeal mucosa from COVID-19 patients versus pre-pandemic controls, with higher reactivity in COVID-19 samples.

    “when comparing samples of nasopharyngeal mucosa from patients with COVID-19 to pre-pandemic biopsy samples from individuals without a manifest respiratory tract infection, a panel of senescence markers was shown to robustly discriminate these two groups, with significantly higher reactivity in samples from patients with COVID-19 (refs.28,29,44,52).”

    From COVID-19 and cellular senescence (2023) · cites this paper as [52]

  • Lung specimens from COVID-19 patients show much stronger signs of senescence than SARS-CoV-2 negative controls.

    “Similar analyses of lung specimens from patients with COVID-19, consistent with multiple independent patient datasets29,44,52, also showed much stronger signs of senescence compared to SARS-CoV-2 negative controls28.”

    From COVID-19 and cellular senescence (2023) · cites this paper as [52]

  • SASP-typical cytokines, extracellular matrix-active proteases, and SASP-related pro-coagulant and complement-activating factors are strongly elevated in the serum of COVID-19 patients compared with healthy controls.

    “were also strongly elevated in the serum of patients with COVID-19 compared to healthy controls28,52,67–70.”

    From COVID-19 and cellular senescence (2023) · cites this paper as [52]

  • SARS-CoV-2 triggers a profibrotic response in CD14+CD163+ macrophages that promotes pulmonary fibrosis and acute respiratory distress syndrome.

    “SARS-CoV-2 triggers a profibrotic response in CD14+CD163+ macrophages, which promotes manifest pulmonary fibrosis and acute respiratory distress syndrome (Box 1)”

    From COVID-19 and cellular senescence (2023) · cites this paper as [52]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Plasma protein elevations attributed to lung tissue

    Minor

    The results say these plasma proteins were elevated in lung tissue, but the methods describe measuring proteins in plasma and analyzing lung tissue for gene expression. The specimen in which the protein elevations were measured is therefore inconsistent.

1 of 1

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
D’Agnillo, F., Walters, K.-A., Xiao, Y., Sheng, Z.-M., Scherler, K., Park, J., Gygli, S., Rosas, L. A., Sadtler, K., Kalish, H., Blatti, C. A., Zhu, R., Gatzke, L., Bushell, C., Memoli, M. J., O’Day, S. J., Fischer, T. D., Hammond, T. C., Lee, R. C., Cash, J. C., Powers, M. E., O’Keefe, G. E., Butnor, K. J., Rapkiewicz, A. V., Travis, W. D., Layne, S. P., Kash, J. C., & Taubenberger, J. K.
Affiliations
  • Center for Biologics Evaluation and Research (US)
  • Institute for Systems Biology (US)
  • National Institutes of Health (US)
  • Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • University of Illinois Urbana-Champaign (US)
  • Saint John’s Cancer Institute, Santa Monica, CA, USA.
  • Saint John's Health Center (US)
  • University of Southern California (US)
  • University of Washington (US)
  • University of Vermont Medical Center (US)
  • NYU Grossman Long Island School of Medicine (US)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
  • D’Agnillo, Felice
  • Walters, Kathie-Anne
  • Xiao, Yongli
  • Sheng, Zong-Mei
  • Taubenberger, Jeffery K.
Venue
Science Translational Medicine
Published
2021-11-17
Volume
13
Issue
620
Pages
eabj7790-eabj7790
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W3205438960
Cited by
237
References
104
Citations by year
2026: 17 · 2025: 39 · 2024: 58 · 2023: 63 · 2022: 58 · 2021: 2
FWCI
15.84
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Science Translational Medicine (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by)
Funders
  • National Institutes of Health
  • National Cancer Institute (P30CA008748)
  • National Institute of Allergy and Infectious Diseases (ZIAAI001271)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
Keywords
COVID-19 pandemic, SARS-CoV-2, fatal COVID-19, lung pathology, alveolar epithelial cell injury, endothelial injury, tissue repair, fibrinolysis, plasminogen activator inhibitor-1, cellular senescence, p21, SIRT1, diffuse alveolar damage, pulmonary thrombosis, lung remodeling, surfactant proteins, alveolar-capillary barrier
MeSH terms
COVID-19, SARS-CoV-2, Fibrinolysis, Humans, Lung, Cellular Senescence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-06.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-06.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review